Background To evaluate the impact of diabetes on outcomes in colorectal cancer patients and to examine whether this association varies by the location of tumor (colon vs. rectum). Patients and methods This study includes 4,131 stage I-III colorectal cancer patients, treated between 1995 and 2007 (12.5% diabetic, 53% colon, 47% rectal) in South Korea. Cox proportional hazards modeling was used to determine the prognostic influence of DM on survival endpoints. Results Colorectal cancer patients with DM had significantly worse disease-free survival (DFS) [hazard ratio (HR) 1.17, 95% confidence interval (CI): 1.00–1.37] compared with patients without DM. When considering colon and rectal cancer independently, DM was significantly associated with worse overall survival (OS) (HR: 1.46, 95% CI: 1.11–1.92), DFS (HR: 1.45, 95% CI: 1.15–1.84) and recurrence-free survival (RFS) (HR: 1.32, 95% CI: 0.98–1.76) in colon cancer patients. No association for OS, DFS or RFS was observed in rectal cancer patients. There was significant interaction of location of tumor (colon vs. rectal cancer) with DM on OS (P = 0.009) and DFS (P = 0.007). Conclusions This study suggests that DM negatively impacts survival outcomes of patients with colon cancer but not rectal cancer.
References
[1]
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA: a cancer journal for clinicians 59: 225–249.
[2]
Organization WH (2010) International Agency for Research on Cancer Higher Blood Vitamin D levels are associated with significantly decreased colon cancer risk in European population, Press release No. 19822, January 2010.
[3]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer 127: 2893–2917.
[4]
Korea TS (2010) The statistics of Cause of Death, Available: http://www.kostat.go.kr.
[5]
Song YM, Sung J, Ha M (2008) Obesity and risk of cancer in postmenopausal Korean women. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26: 3395–3402.
[6]
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. (2008) Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26: 4109–4115.
[7]
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, et al. (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22: 648–657.
[8]
Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American journal of clinical nutrition 86: s836–842.
[9]
Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132: 2208–2225.
[10]
Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, et al. (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA : the journal of the American Medical Association 293: 194–202.
[11]
Williams JC, Walsh DA, Jackson JF (1984) Colon carcinoma and diabetes mellitus. Cancer 54: 3070–3071.
[12]
Sandhu MS, Dunger DB, Giovannucci EL (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. Journal of the National Cancer Institute 94: 972–980.
[13]
Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, et al. (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. International journal of cancer Journal international du cancer 121: 368–376.
[14]
Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, et al. (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. Journal of the National Cancer Institute 92: 1592–1600.
[15]
Kaczka A, Kumor A, Pietruczuk M, Malecka-Panas E (2007) [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 22: 373–375.
[16]
Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, et al.. (2011) Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? The American journal of gastroenterology 106: 1911–1921; quiz 1922.
[17]
Limburg PJ, Anderson KE, Johnson TW, Jacobs DR Jr, Lazovich D, et al. (2005) Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women’s Health Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14: 133–137.
[18]
Iacopetta B (2002) Are there two sides to colorectal cancer? International journal of cancer Journal international du cancer 101: 403–408.
[19]
Breivik J, Lothe RA, Meling GI, Rognum TO, Borresen-Dale AL, et al. (1997) Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. International journal of cancer Journal international du cancer 74: 664–669.
[20]
Lindblom A (2001) Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Current opinion in oncology 13: 63–69.
[21]
Shonka NA, Anderson JR, Panwalkar AW, Reed EC, Steen PD, et al. (2006) Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer. Medical oncology 23: 515–519.
[22]
Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, et al. (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21: 433–440.
[23]
Huang YC, Lin JK, Chen WS, Lin TC, Yang SH, et al. (2011) Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. Journal of cancer research and clinical oncology 137: 211–220.
[24]
Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. American journal of epidemiology 159: 1160–1167.
[25]
Noh GY, Hwang DY, Choi YH, Lee YY (2010) Effect of diabetes mellitus on outcomes of colorectal cancer. Journal of the Korean Society of Coloproctology 26: 424–428.
[26]
Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, et al. (2012) Impact of Diabetes Mellitus and Insulin Use on Survival After Colorectal Cancer Diagnosis: The Cancer Prevention Study-II Nutrition Cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30: 53–59.
[27]
Morrison DS, Batty GD, Kivimaki M, Davey Smith G, Marmot M, et al. (2011) Risk factors for colonic and rectal cancer mortality: evidence from 40 years’ follow-up in the Whitehall I study. Journal of epidemiology and community health 65: 1053–1058.
[28]
Moore MA, Sobue T, Kuriki K, Tajima K, Tokudome S, et al. (2005) Comparison of Japanese, American-Whites and African-Americans–pointers to risk factors to underlying distribution of tumours in the colorectum. Asian Pacific journal of cancer prevention : APJCP 6: 412–419.
[29]
Yu J, Shin CH, Yang SW, Park MH, Eisenbarth GS (2004) Analysis of children with type 1 diabetes in Korea: high prevalence of specific anti-islet autoantibodies, immunogenetic similarities to Western populations with “unique” haplotypes, and lack of discrimination by aspartic acid at position 57 of DQB. Clinical immunology 113: 318–325.
[30]
Harriss DJ, Atkinson G, George K, Cable NT, Reilly T, et al. (2009) Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 11: 547–563.
[31]
Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, et al. (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. Journal of the National Cancer Institute 91: 542–547.
[32]
Lim E, Jones IT, Gibbs P, McLaughlan S, Faragher I, et al. (2005) Subsite-specific colorectal cancer in diabetic and nondiabetic patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14: 1579–1582.
[33]
Tavani A, Bravi F, Bosetti C, Franceschi S, Levi F, et al. (2005) Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women’s Health Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14: 2277.
[34]
van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, et al. (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. International journal of cancer Journal international du cancer 120: 1986–1992.
[35]
Caudle AS, Kim HJ, Tepper JE, O’Neil BH, Lange LA, et al. (2008) Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol 15: 1931–1936.
[36]
Carmona FJ, Esteller M (2011) Moving closer to a prognostic DNA methylation signature in colon cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17: 1215–1217.
[37]
Li Q, Chen H (2011) Epigenetic modifications of metastasis suppressor genes in colon cancer metastasis. Epigenetics : official journal of the DNA Methylation Society 6: 849–852.
[38]
Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, et al. (2004) Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. Journal of the National Cancer Institute 96: 1015–1022.
[39]
Larsson SC, Rutegard J, Bergkvist L, Wolk A (2006) Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. European journal of cancer 42: 2590–2597.
[40]
Li M, Li JY, Zhao AL, Gu J (2007) Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology 73: 52–57.
[41]
Sun L, Yu S (2012) Diabetes mellitus is an independent risk factor for colorectal cancer. Dig Dis Sci 57: 1586–1597.
[42]
Deng L, Gui Z, Zhao L, Wang J, Shen L (2012) Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 57: 1576–1585.
[43]
Polednak AP (2006) Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. Cancer detection and prevention 30: 466–472.
[44]
Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, et al.. (2011) Impact of Diabetes Mellitus and Insulin Use on Survival After Colorectal Cancer Diagnosis: The Cancer Prevention Study-II Nutrition Cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45]
Giouleme O, Diamantidis MD, Katsaros MG (2011) Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 17: 444–448.
[46]
Berster JM, Goke B (2008) Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114: 84–98.
[47]
Bach LA, Rechler MM (1992) Insulin-like growth factors and diabetes. Diabetes Metab Rev 8: 229–257.
[48]
Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, et al. (2011) Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis 12: 234–244.
[49]
Salageanu A, Tucureanu C, Lerescu L, Caras I, Pitica R, et al. (2010) Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life 3: 416–420.
[50]
Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254–258.
[51]
Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53: 1631–1637.
[52]
Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, et al. (2011) Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34: 2323–2328.
